home / stock / mxct / mxct articles
MaxCyte Inc (NASDAQ: MXCT) shares plummeted after the company released preliminary Q3 revenue of $7.8 million – 8.0 million, a Y/Y decre...
U.S. stocks traded slightly lower toward the end of trading, with the Dow Jones index falling around 40 points on Thursday. The Dow traded down 0.1...
Gainers Orchard Therapeutics plc (NASDAQ: ORTX) shares climbed 97.7% to $15.98 after the company agreed to be acquired by Japan's Kyowa Kirin...
Gainers Orchard Therapeutics plc (NASDAQ: ORTX) shares rose 95.5% to $15.80 in pre-market trading after the company inked a deal with Kyowa Kirin...
U.S. stock futures traded lower this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session. C...
With U.S. stock futures trading lower this morning on Thursday, some of the stocks that may grab investor focus today are as follows: Wall Street ...
ROCKVILLE, Md., Sept. 05, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading commercial cell-engineering company focus...
The Company has developed an innovative platform with a highly effective revenue model in place, which should help it rise to new heights.
News, Short Squeeze, Breakout and More Instantly...
ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioproce...
ROCKVILLE, Md., May 29, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bio...
ROCKVILLE, Md., May 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc . , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics and inn...